MichaelDHogartyMD
Pediatric Hematology & Oncology • Philadelphia, PAAssociate Professor, Pediatrics, Perelman School of Medicine
Are you Dr. Hogarty?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Connect with colleagues in the same hospital or clinic
You already have 61 invites waiting! - Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
3401& Civic Center Blvd
Children's Hospital Of Philadelphia - Hem/Onc
Philadelphia, PA 19104Phone+1 215-590-3535Fax+1 215-590-3992- Is this information wrong?
Summary
- Dr. Michael Hogarty, MD is a pediatric hematologist/oncologist in Philadelphia, Pennsylvania. He is currently licensed to practice medicine in Pennsylvania and Illinois. He is affiliated with Children's Hospital of Philadelphia and is an Associate Professor at Perelman School of Medicine.
Education & Training
Children's Hospital of PhiladelphiaFellowship, Pediatric Hematology/Oncology, 1994 - 1997
McGaw Medical Center of Northwestern UniversityResidency, Pediatrics, 1990 - 1994
Columbia University Vagelos College of Physicians and SurgeonsClass of 1990
Certifications & Licensure
PA State Medical License 1994 - 2024
IL State Medical License 1990 - 1996- American Board of Pediatrics Pediatric Hematology-Oncology
Clinical Trials
- Study of DNA in Blood Samples From Patients With Neuroblastoma Start of enrollment: 2007 Jun 01
- Biomarkers in Tumor Tissue Samples From Patients With Newly Diagnosed Neuroblastoma or Ganglioneuroblastoma Start of enrollment: 2000 Nov 06
- Study of Specimens From Young Patients With Neuroblastoma Start of enrollment: 2008 Dec 01
Publications & Presentations
PubMed
- Clofarabine monotherapy in aggressive, relapsed and refractory Langerhans cell histiocytosis.Agrusa, J. E., Deevyashali Parekh, Howard Lin, Akanksha Batajoo, Erin Peckham-Gregory, Vivekanudeep Karri, Whitney Stanton, Brooks Scull, Ryan Fleishmann, Nader El-Mal...> ;British Journal of Haematology. 2024 Mar 19
- Phase 1 study of high-dose DFMO, celecoxib, cyclophosphamide and topotecan for patients with relapsed neuroblastoma: a New Approaches to Neuroblastoma Therapy trial.Michael D Hogarty, David S Ziegler, Andrea Franson, Yueh-Yun Chi, Denice Tsao-Wei, Kangning Liu, Rohan Vemu, Eugene W Gerner, Elizabeth Bruckheimer, Anasheh Shamirian,...> ;British Journal of Cancer. 2024 Mar 1
- Reprogramming neuroblastoma by diet-enhanced polyamine depletion.Cherkaoui, S., Yang, L., McBride, M., Turn, C., Lu, W., Eigenmann, C., Allen, G., Panasenko, O., Zhang, L., Vu, A., Liu, K., Li, Y., Gandhi, O., Surrey, L., Wierer, M....> ;Biorxiv. 2024 Jan 8
- Join now to see all
Press Mentions
- CHOP Researchers Uncover Unique Mechanism for Cancer Therapy ResistanceApril 1st, 2022
- Panbela Announces Publication of Clinical Data Titled: Phase 1 Study of High-Dose DFMO, Celecoxib, Cyclophosphamide and Topotecan for Patients with Relapsed Neuroblastoma: A New Approaches to Neuroblastoma Therapy TrialJanuary 23rd, 2024
Hospital Affiliations
Children's Hospital of PhiladelphiaPhiladelphia, Pennsylvania
